Getty Images A new clinical trial shows the immunotherapy drug dostarlimab could eliminate the need for surgery and chemotherapy in certain cancers. The results are a medical breakthrough since ...

A new clinical trial shows the immunotherapy drug dostarlimab could eliminate the need for surgery and chemotherapy in certain cancers. The results are a medical breakthrough since the drug could ...

Most study participants were able to avoid operations after taking dostarlimab. A new study in the New England Journal of Medicine suggests that some people with early stage cancers may be able to ...

Dostarlimab treatment led to complete clinical responses in 82% of patients with dMMR tumors, avoiding surgery for most. Recurrence-free survival at two years was 92%, with a median follow-up of ...

A group of 18 colorectal cancer patients experienced complete remission after taking the experimental drug dostarlimab for six months. The trial conducted at Memorial Sloan Kettering Cancer Center ...

Dostarlimab has been watched closely by oncologists since its trial on rectal cancer patients at Memorial Sloan Kettering Cancer Center. It eradicated patient tumors, and they've remained cancer-free.

For the past 10 years, filmmaker Lawrence Lek has been creating science-fiction landscapes that feature neon temples, drones touring abandoned luxury hotels, and empty urban highways. The ...

Part 1 is evaluating dostarlimab plus carboplatin-paclitaxel followed by dostarlimab versus carboplatin-paclitaxel plus placebo followed by placebo. Part 2 is evaluating dostarlimab plus ...

PHILADELPHIA, August 01, 2024--(BUSINESS WIRE)--GSK plc (LSE/NYSE: GSK) today announced the US Food and Drug Administration (FDA) has approved Jemperli (dostarlimab-gxly) in combination with ...

We believe belrestotug + dostarlimab are poised to potentially advance the therapeutic regimen in this setting and establish new benchmarks,” said Michel Detheux, Ph.D., president and chief ...

Jemperli, also called dostarlimab, showed "unprecedented results", maker GSK said, with no evidence of disease in all patients treated. Everyone on the medication had locally advanced mismatch ...